Inventor

YANG JU

US66 patents

⚠️ This page may combine multiple inventors who share the name “YANG JU”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

CHEMOCENTRYX INC

41 patents

US10639284B2May 5, 2020

Immunomodulator compounds

CHEMOCENTRYX INC17 citations94

US10035768B2Jul 31, 2018

C5aR antagonists

CHEMOCENTRYX INC23 citations94

US9834545B2Dec 5, 2017

Modulators of chemokine receptors

CHEMOCENTRYX INC26 citations94

US9809581B2Nov 7, 2017

Inhibitors of CXCR2

CHEMOCENTRYX INC23 citations94

US9573897B2Feb 21, 2017

C5AR antagonists

CHEMOCENTRYX INC24 citations94

US8906938B2Dec 9, 2014

C5aR antagonists

CHEMOCENTRYX INC28 citations92

US11485708B2Nov 1, 2022

Compounds for treatment of PD-L1 diseases

CHEMOCENTRYX INC9 citations86

US11426364B2Aug 30, 2022

Immunomodulator compounds

CHEMOCENTRYX INC10 citations86

US11266643B2Mar 8, 2022

Triaryl compounds for treatment of PD-L1 diseases

CHEMOCENTRYX INC13 citations86

US11135210B2Oct 5, 2021

Indane-amines as PD-L1 antagonists

CHEMOCENTRYX INC10 citations86

US10568874B2Feb 25, 2020

Indane-amines as PD-L1 antagonists

CHEMOCENTRYX INC13 citations86

US11713307B2Aug 1, 2023

Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases

CHEMOCENTRYX INC8 citations85

US10919852B2Feb 16, 2021

Immunomodulator compounds

CHEMOCENTRYX INC15 citations85

US11142521B2Oct 12, 2021

Substituted anilines as CCR(4) antagonists

CHEMOCENTRYX INC4 citations84

US10660897B2May 26, 2020

C5aR antagonists

CHEMOCENTRYX INC6 citations84

US10370363B2Aug 6, 2019

Inhibitors of CXCR2

CHEMOCENTRYX INC6 citations84

US10336736B2Jul 2, 2019

Modulators of chemokine receptors

CHEMOCENTRYX INC6 citations84

US9758512B2Sep 12, 2017

Substituted anilines as CCR(4) antagonists

CHEMOCENTRYX INC6 citations84

US9567323B2Feb 14, 2017

Substituted anilines as CCR(4) antagonists

CHEMOCENTRYX INC6 citations84

US8835419B2Sep 16, 2014

Substituted anilines as CCR(4) antagonists

CHEMOCENTRYX INC9 citations83

US9340509B2May 17, 2016

CCR6 compounds

CHEMOCENTRYX INC4 citations82

US11708326B2Jul 25, 2023

Immunomodulator compounds

CHEMOCENTRYX INC4 citations74

US11446289B2Sep 20, 2022

Combination therapy using C-C chemokine receptor 4 (CCR4) antagonists and one or more immune checkpoint inhibitors

CHEMOCENTRYX INC3 citations73

US11434230B2Sep 6, 2022

2-oxindole compounds

CHEMOCENTRYX INC1 citations73

US11040960B2Jun 22, 2021

Inhibitors of CXCR2

CHEMOCENTRYX INC3 citations73

US10988464B2Apr 27, 2021

Modulators of chemokine receptors

CHEMOCENTRYX INC3 citations73

US10759789B2Sep 1, 2020

2-oxindole compounds

CHEMOCENTRYX INC2 citations73

US10421748B2Sep 24, 2019

2-oxindole compounds

CHEMOCENTRYX INC3 citations73

US10407417B2Sep 10, 2019

Substituted anilines as CCR(4) antagonists

CHEMOCENTRYX INC3 citations73

US9790204B2Oct 17, 2017

Substituted benzimidazoles and benzopyrazoles as CCR(4) antagonists

CHEMOCENTRYX INC2 citations73

US11427541B2Aug 30, 2022

Salt forms of a complement component C5A receptor

CHEMOCENTRYX INC2 citations72

US9795599B2Oct 24, 2017

CCR6 compounds

CHEMOCENTRYX INC2 citations72

US9150550B2Oct 6, 2015

Substituted benzimidazoles and benzopyrazoles as CCR(4) antagonists

CHEMOCENTRYX INC2 citations63

US8685959B2Apr 1, 2014

Substituted benzimidazoles and benzopyrazoles as CCR(4) antagonists

CHEMOCENTRYX INC2 citations63

US12533354B2Jan 27, 2026

Triaryl compounds for treatment of PD-L1 diseases

CHEMOCENTRYX INC0 citations62

US12497383B2Dec 16, 2025

Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases

CHEMOCENTRYX INC0 citations62

US12371433B2Jul 29, 2025

Heteroaryl-biphenyl amines for the treatment of PD-L1 diseases

CHEMOCENTRYX INC0 citations62

US12139475B2Nov 12, 2024

2-oxindole compounds

CHEMOCENTRYX INC0 citations62

US12011439B2Jun 18, 2024

Combination therapy using C—C chemokine receptor 4 (CCR4) antagonists and one or more immune checkpoint inhibitors

CHEMOCENTRYX INC0 citations62

US11945805B2Apr 2, 2024

Inhibitors of CXCR2

CHEMOCENTRYX INC0 citations62

US11884654B2Jan 30, 2024

Substituted anilines as CCR(4) antagonists

CHEMOCENTRYX INC0 citations62

SHENZHEN DANCING FUTURE TECH LTD

4 patents

USD1034539SJul 9, 2024

Earphone

SHENZHEN DANCING FUTURE TECH LTD32 citations93

USD1054397SDec 17, 2024

Earphone

SHENZHEN DANCING FUTURE TECH LTD13 citations84

USD1074586SMay 13, 2025

Earphone case

SHENZHEN DANCING FUTURE TECH LTD2 citations73

USD1024031SApr 23, 2024

Earphone

SHENZHEN DANCING FUTURE TECH LTD3 citations73

BOSE CORP

2 patents

USD798339SSep 26, 2017

Wireless audio adapter

BOSE CORP51 citations98

USD767529SSep 27, 2016

Audio amplifier

BOSE CORP5 citations73

FAN PINGCHEN

2 patents

US9126939B2Sep 8, 2015

C5AR antagonists

FAN PINGCHEN30 citations93

US8445515B2May 21, 2013

C5aR antagonists

FAN PINGCHEN38 citations93

YANG GUAN

1 patent

US9988009B2Jun 5, 2018

Separated anti-collision car

YANG GUAN5 citations64

Showing the top 50 of 66 patents by PatentIndex Score.